Novel Sedatives Beyond Benzos: Dicloqualone, 2-Methoxyqualone and RC Quaalude Analogues

Novel Sedatives Beyond Benzos: Dicloqualone, 2-Methoxyqualone and RC Quaalude Analogues

Quick answer

The RC depressant world is broader than designer benzodiazepines.

One smaller but recurring family is made up of quinazolinone sedatives related to methaqualone, the drug historically sold as Quaalude in the United States and Mandrax in some other markets.

Modern examples include dicloqualone (SL-164) and the much newer 2-methoxyqualone.

The evidence for these compounds is far thinner than the evidence for prescription benzodiazepines. That makes the correct default uncertainty, not nostalgia-driven assumptions about “Quaalude-like” safety or effects.

Why methaqualone analogues keep resurfacing

Methaqualone became famous for sedative, hypnotic and disinhibiting effects before its medical use ended and international controls expanded.

RC markets periodically revisit older drug-discovery chemistry looking for structurally related compounds that were never widely marketed.

That does not mean those analogues were rejected because they were safe-but-forgotten. Often the available modern human data are almost nonexistent.

Dicloqualone / SL-164

CFSRE confirmed dicloqualone in U.S. drug material and describes it as a quinazolinone with structural similarity to methaqualone.

Available pharmacology suggests sedative effects involving GABA receptor activity.

The important limitation is that modern controlled human safety data are not available.

2-Methoxyqualone

2-Methoxyqualone is an even newer signal.

CFSRE reported U.S. drug-material detections in 2026 and stated that no published pharmacological potency data were available at the time of its report.

Its structural similarity to methaqualone creates a hypothesis of sedative-hypnotic activity. It does not create a clinical safety profile.

Why combining sedatives is dangerous

Whether the depressant is a benzodiazepine, qualone analogue, alcohol, gabapentinoid, opioid or another sedative, overlapping central nervous system depression can increase impairment and loss of consciousness.

Opioids add the specific danger of respiratory depression.

A gray-market product may also contain more than one depressant without the buyer knowing.

Related evidence

• Designer benzodiazepines
• Dicloqualone / SL-164
• 2-Methoxyqualone
• Research chemicals & NPS evidence map

A practical framework for reading novel-sedative evidence

“Novel sedative” is a market and pharmacology umbrella, not a guarantee that every member behaves like methaqualone or a prescription benzodiazepine. The family includes compounds with different structures, metabolism, receptor profiles, and amounts of human evidence. For that reason, this page treats identity, mechanism, clinical effects, and forensic detection as separate evidence layers.

Analytical confirmation can prove that a compound has entered drug material. Receptor or animal work can make a sedative mechanism plausible. Human toxicology can document actual poisonings. Those layers should not be collapsed into a single potency ranking, because a strong receptor signal does not reveal a safe human exposure and a single case cannot define population risk.

Dependence and withdrawal

Repeated use of a sedative-hypnotic can create tolerance and physical dependence, but the evidence is uneven across newer qualone analogues. A class warning is therefore justified; a one-size-fits-all withdrawal calendar is not. When a person has been using an unknown or poorly characterized sedative regularly, delayed symptoms and co-exposure to alcohol, benzodiazepines, opioids, or other depressants can complicate the picture.

Product identity and testing

Unregulated sedatives create two uncertainties at once: what molecule is present and how much is present. Tablet color, branding, powder appearance, or a vendor label cannot resolve either question. Routine immunoassays also do not cover every novel quinazolinone or sedative analogue. Laboratory confirmation may require LC-MS/MS or high-resolution mass spectrometry with current reference data.

What this hub will not do

This library does not turn sparse evidence into dose tables, redosing intervals, “equivalent” amounts, or do-it-yourself withdrawal schedules. It also does not treat forum reports as proof of identity. The useful job of a family hub is to show readers which compounds have meaningful human evidence, which have only analytical or preclinical evidence, and where the uncertainties are still large enough that confident claims would be misleading.

Bottom line

RC sedatives should not be reduced to “benzos.”

Methaqualone analogues have re-entered drug markets, but modern human evidence is extremely thin. A familiar historical drug name does not make a new analogue predictable.